Immunotherapy drugs for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) based on a biopsy or imaging scans.
- Your cancer is at BCLC stage B (and it's widespread or has worsened after TACE) or stage C (advanced).
- You have not had any prior cancer-fighting drugs given through your whole body (systemic therapy) for liver cancer.
- Your liver function is good (Child-Pugh class A) and you are able to do your daily activities (ECOG score 0 or 1).
- Your blood counts and kidney/liver function meet certain levels (like hemoglobin ≥ 9 g/dL, platelets ≥ 75,000, and creatinine clearance ≥ 50 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This trial is testing how well immune checkpoint inhibitors, which help the body's immune system fight cancer, work in people with advanced liver cancer. The goal is to see if these drugs are effective and safe for patients whose liver is still working reasonably well.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.